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The Korean government established an antimicrobial 
resistance (AMR) surveillance system, compatible 
with the Global AMR Surveillance System (GLASS): 
Kor-GLASS. We describe results from the first year of 
operation of the Kor-GLASS from May 2016 to April 
2017, comprising all non-duplicated clinical isolates 
of major pathogens from blood,urine,  faeces and 
urethral and cervical swabs from six sentinel hos-
pitals. Antimicrobial susceptibility tests were car-
ried out by disk diffusion, Etest, broth microdilution 
and agar dilution methods. Among 67,803 blood 
cultures, 3,523 target pathogens were recovered. 
The predominant bacterial species were  Escherichia 
coli  (n = 1,536),  Klebsiella pneumoniae  (n = 
597) and  Staphylococcus aureus  (n = 584). From 
57,477 urine cultures, 6,394  E. coli  and 1,097  K. 
pneumoniae  were recovered. Bloodstream infections 
in inpatients per 10,000 patient-days (10TPD) were 
highest for cefotaxime-resistant  E. coli  with 2.1, fol-
lowed by 1.6 for meticillin-resistant Sta. aureus, 1.1 for 
imipenem-resistant  Acinetobacter baumannii, 0.8 for 
cefotaxime-resistant  K. pneumoniae  and 0.4 for van-
comycin-resistant Enterococcus faecium. Urinary tract 
infections in inpatients were 7.7 and 2.1 per 10TPD 
for cefotaxime-resistant  E. coli  and  K. pneumoniae, 
respectively. Kor-GLASS generated well-curated sur-
veillance data devoid of collection bias or isolate 
duplication. A bacterial bank and a database for the 
collections are under development.
Introduction
Antimicrobial resistance (AMR) is a growing burden 
in both clinical and socioeconomic context owing 
to the high morbidity and prolonged hospitalisation 
of patients that causes elevated medical and soci-
etal costs because of loss of productivity [1]. The 
World Health Organization launched the Global AMR 
Surveillance System (GLASS) in 2015 [2] as a core 
global action plan addressing this issue. The standard-
ised GLASS manual allowed an overview of global AMR 
rates through international comparison.
An AMR surveillance system in South Korea, the Korean 
AMR Monitoring System (KARMS), had been operated 
between 2002 and 2015 by Korean Centers for Disease 
Control and Prevention (KCDC) [3,4]. KARMS played 
an important role in notifying the high AMR rates in 
South Korea, urging the government to develop a 
national action plan. However, this system had limita-
tions. Firstly, the antimicrobial susceptibility testing 
(AST) methods were not well harmonised across the 
participating clinical laboratories, affecting reliability. 
Secondly, duplicated isolates were not sufficiently fil-
tered out, which could lead to an overestimation of the 
national AMR rates. Finally, the epidemiological inter-
pretation of the study was limited because of insuffi-
cient clinical data.
From KARMS, the KCDC established an improved AMR 
surveillance system compatible with the GLASS, named 
Kor-GLASS [5]. The Kor-GLASS manual was customised 
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from that of GLASS: (i) three bacterial species from 
blood specimens were added, namely Enterococcus fae-
calis and Enterococcus faecium  to monitor vancomycin 
resistance and  Pseudomonas aeruginosa  to monitor 
carbapenem resistance and (ii) more target antimicro-
bial agents for AST were included to investigate multi-
drug resistance by species.
We have operated the Kor-GLASS for one year since 
May 2016 and report here the first one-year assess-
ment until April 2017.
Methods
Collection of isolates and clinical data from 
sentinel hospitals
The six sentinel hospitals collected bacterial isolates 
and clinical data, and all tests were performed in 
a central laboratory [5]. We collected all non-dupli-
cated clinical isolates of  Staphylococcus aureus, 
Streptococcus pneumoniae, Ent. faecalis, Ent. fae-
cium,  Acinetobacter  spp., and  P. aeruginosa  from 
blood, Escherichia coli and Klebsiella pneumoniae from 
both blood and urine, Salmonella spp. from both blood 
and faeces,  Shigella  spp. from faeces and  Neisseria 
Figure 1
Number of patients sampled for bacterial culture, by specimen and age group, South Korea, May 2016–April 2017
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Patients are shown grouped by origin of infections. Detailed numbers can be found in Table 1 in the Supplement.
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gonorrhoeae  from urethral and cervical swabs. Urine 
isolates were collected through semi-quantifying 
culture of urine samples following the criteria: (i) 
≥104  colony-forming units (CFU)/mL single-species 
growth of either  E. coli  or  K. pneumoniae  and (ii) 
≥105  CFU/mL of  E. coli  or  K. pneumoniae  in growth of 
mixed species [6]. We recorded epidemiological data 
including age, sex, infection origin (hospital origin 
(HO) or community origin (CO)) and admission types 
(outpatient department (OPD), general ward (GW), 
intensive care unit (ICU)) of all patients from whom 
blood, urine, stool or genital cultures were taken dur-
ing study period. HO was defined when the specimen 
was taken from a patient hospitalised for two or more 
calendar days overall, including the hospitalisation 
days in another healthcare facility before transfer. CO 
Figure 2
Occurrence of bloodstream and urinary tract infections per 10,000 patient-days, by target pathogen, South Korea, May 
2016–April 2017 (total patient days = 1,620,431)
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The figure shows mean occurrence across all six hospitals, with the lowest and highest indicated by error bars.
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Figure 3
Percentage of resistance to major antimicrobials by infection origin, South Korea, May 2016–April 2017 (Part I: panels A–F)
Amox-Clav: amoxicillin-clavulanic acid; Amp-Sulb: ampicillin-sulbactam; CO: community origin; HO: hospital origin; Gentamicin-HL: high-level 
resistance to gentamicin; Pio-Tazob: piperacillin-tazobactam; Quin-Dalf: quinupristin-dalfopristin; Streptomycin-HL: high-level resistance to 
streptomycin; Trim-Sulf: trimethoprim-sulfamethoxazole.
Detailed numbers can be found in Tables 2–7 in the Supplement.
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Figure 4
Percentage of resistance to major antimicrobials by infection origin, South Korea, May 2016–April 2017 (Part II: panels 
G–L)
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Figure 5
Occurrence of bloodstream and urinary tract infections per 10,000 patient-days, by major antimicrobial resistant pathogen, 
South Korea, May 2016–April 2017 (total patient days = 1,620,431)
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The figure shows mean occurrence across all six hospitals, with the lowest and highest indicated by error bars.
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was defined when the specimen was taken either from 
an outpatient or from a patient hospitalised for less 
than 2 calendar days.
Microbiological analysis in the central 
laboratory
Bacterial species were re-checked in the central labo-
ratory using a Bruker Biotyper (Bruker Daltonics GmbH, 
Bremen, Germany) and/or by nucleotide sequence 
analysis of the 16S rDNA or rpoB  (for Acinetobacter sp
p.). AST was carried out by disk diffusion, Etest, and 
broth microdilution and agar dilution methods follow-
ing the Clinical and Laboratory Standards Institute 
guidelines [7]. Antimicrobial susceptibility phenotypes 
were categorised according to Magiorakos et al. [8] 
with a few modifications:
• fully susceptible (DS): susceptible to all tested drugs;
• drug-resistant (DR): non-susceptible to one or two 
drug classes;
• multidrug-resistant (MDR): non-susceptible to three 
or more antimicrobial classes;
• extensively drug-resistant (XDR): susceptible to two 
or fewer antimicrobial classes;
• pandrug-resistant (PDR): not susceptible to any anti-
microbial class.
Double-blinded inter-laboratory parallel tests were 
conducted monthly for randomly selected isolates in 
order to evaluate proficiency of the results from central 
and the national KCDC reference laboratories.
Results
Target pathogen isolation from the collected 
cultures
During the 1-year period, six sentinel hospitals sam-
pled 67,803 patients for blood culture, 57,477 for 
urine, 12,782 for stool and 3,111 for genital cultures 
(Figure 1). A total of 3,523 (5.2%) target pathogens 
were recovered from blood (Supplement: supple-
mentary figure 1). The predominant bacterial species 
was  E. coli  (n = 1,536, 43.6%), followed by  K. pneu-
moniae  (n = 597, 16.9%) and  Sta. aureus  (n = 584, 
16.6%).  Acinetobacter  spp. was recovered more often 
(n = 229, 6.5%) than  P. aeruginosa  (n = 127, 3.6%). 
The majority of  Acinetobacter  spp. were  A. bauman-
nii  (188/229, 82.1%); the remaining 41 were non-
baumannii Acinetobacter  spp. (NBA), composed of  A. 
nosocomialis  (n = 23),  A. pittii  (n = 12),  A. berezin-
iae  (n = 2),  A. soli  (n = 2),  A. radioresistens  (n = 1) 
and Acinetobacter genomospecies 14TU (n = 1). Ent. fae-
cium (n = 217, 6.2%) was recovered more often than Ent. 
faecalis  (n = 161, 4.6%).  Salmonella  spp. (n = 44, 
1.2%) and  Str. pneumoniae  (n = 28, 0.8%) were rarely 
recovered. 
Rates of bloodstream infection (BSI) occurrence among 
inpatients per 10,000 patient-days (10TPD) were calcu-
lated by bacterial pathogen (Figure 2). The total num-
ber of patient-days in the six sentinel hospitals during 
the surveillance period was 1,620,431 days, comprising 
181,967 days in ICU and 1,438,464 days on a GW. The 
highest mean rate of BSI was found for E. coli with 5.5 
(range: 1.4–12.2 by hospital), followed by 2.8 for  Sta. 
aureus  (range: 1.1–6.7), 2.5 for  K. pneumoniae  (range: 
1.0–5.1), 1.2 for Ent. faecium (range: 0.5–1.7), 1.1 for A. 
baumannii (range: 0.8–1.7), 0.8 for Ent. faecalis (range: 
0.3–1.8) and 0.6 for  P. aeruginosa  (range: 0.1–1.1). 
BSI occurrence was more common in ICU patients 
than in GW patients: the ratio of ICU:GW was high-
est in  A. baumannii  at 16.5 (6.6:0.4), followed by 6.0 
(3.0:0.5) in  Ent. faecalis, 4.4 (8.8:2.0) in  Sta. aureus, 
4.0 (3.6:0.9) in Ent. faecium, 3.4 (1.7:0.5) in P. aerugi-
nosa, 2.7 (5.7:2.1) in  K. pneumoniae, and 1.8 (9.0:5.1) 
in E. coli.
From the 57,477 urine cultures, 6,394 (11.1%) E. coli and 
1,097 (1.9%) K. pneumoniae were recovered. The mean 
rate of  E. coli  urinary tract infection (UTI) occurrence 
among inpatients per 10TPD was 20.7 (range: 4.4–32.7 
by hospital) and that caused by K. pneumoniae was 4.7 
(range: 2.0–8.3). The ratio of UTI occurrence in ICU:GW 
was higher in K. pneumoniae  (2.5, 10.0:4.0) than in E. 
coli  (1.4, 26.9:19.9). From the 12,782 stool cultures, 
77 Salmonella spp. (0.6%) were recovered. None of the 
3,111 genital cultures were positive for N. gonorrhoeae.
Antimicrobial susceptibilities of major 
pathogens
Gram-positive pathogens
More than half (317/584, 54.3%) of  Sta. aureus  blood 
isolates were resistant to cefoxitin (Figures 3  and  4), 
which means that these were meticillin-resistant  Sta. 
aureus (MRSA). By origin of infection, 69.4% (213/307) 
of HO  Sta. aureus  were MRSA, more than the 37.5% 
(104/277) of CO. Most of the isolates remained 
susceptible to linezolid, tigecycline and quinupristin-
dalfopristin, and they were all susceptible to vancomy-
cin and teicoplanin. The Sta. aureusblood isolates were 
categorised as DS (35.8%, n = 209), DR (9.9%, n = 58) 
and MDR (54.3%, n = 317), and all MDR isolates were 
MRSA (Supplement: supplementary figure 2).
While resistance to ampicillin in  Ent. faecalis  blood 
isolates was rare (1/161, 0.6%), the proportion of 
penicillin resistance was comparably high (n = 36, 
22.4%) and more frequent in HO (24/90, 26.7%) than 
in CO (12/71, 16.9%). Resistance to glycopeptides 
was also rare (Figures 3 and 4). The rate of high-level 
resistance [7] to aminoglycosides was 38.5% (n = 62) 
to gentamicin and 18.0% (n = 29) to streptomycin. 
The majority of the  Ent. faecalis  blood isolates were 
either DR (49.1%, n = 79) or MDR (42.2%, n = 68). 
The proportion of multidrug resistance in penicillin-
resistant isolates was three times higher (86.1%, 
31/36) than that in susceptible ones (29.6%, 37/125).
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Among the 217  Ent. faecium  blood isolates, 90.3% 
(n = 196) were resistant to ampicillin and 29.0% 
(n = 63) and 18.4% (n = 40) were resistant to 
vancomycin and teicoplanin, respectively. For these 
drugs, resistance rates in HO isolates were higher than 
those in CO isolates (Figures 3  and  4). Forty of the 
63 vancomycin-resistant  Ent. faecium  (VREFM) were 
also resistant to teicoplanin and 14 were intermedi-
ate, while nine remained susceptible to the drug. In 
addition, 27.6% (n = 60) and 10.1% (n = 22) of all Ent. 
faecium  were high-level resistant to gentamicin and 
streptomycin, respectively. Two thirds of the  Ent. fae-
cium  blood isolates were MDR (62.7%, n = 136) and 
one third was DR (33.2%, n = 72). All VREFM isolates 
were categorised as MDR.
All  Str. pneumoniae  blood isolates were susceptible 
(23/28) or intermediate (n = 5) to penicillin. The 
five penicillin-intermediate isolates were also non-
susceptible to other drugs. All 28 isolates were 
susceptible to levofloxacin. Erythromycin resistance 
was observed in 21 of the 28 isolates.
Enterobacteriaceae
Ampicillin resistance was identified in 65.6% 
(1,007/1,536) of  E. coli  blood isolates and decreased 
to 24.2% (n = 372) when sulbactam was supple-
mented. Rates of resistance to cefotaxime, ceftazidime 
and cefepime were 34.7% (n = 533), 11.3% (n = 173) 
and 21.0% (n = 322), respectively. Carbapenem-non-
susceptible isolates were rarely identified. The resist-
ance rate to ciprofloxacin was 39.5% (n = 606) and 
that to amikacin was low at 0.7% (n = 11). Colistin-
resistant isolates were seldom identified, with 0.2% 
(n = 3). Resistance rates in  E. coli  urine isolates were 
similar to those in blood isolates. One isolate was 
resistant to all three carbapenems and six were non-
susceptible only to ertapenem. Colistin resistance was 
detected in 14 (0.2%) of the 6,394 E. coli urine isolates. 
HO isolates had higher resistance rates to most of 
the tested antimicrobials than CO isolates, and this 
difference was much greater in blood isolates than in 
urine isolates. The vast majority (98.8%, 2,616/2,648) 
of cefotaxime-non-susceptible  E. coli  isolates were 
MDR and all XDR isolates (0.2%, 15/7,930) were non-
susceptible to both carbapenems and cefotaxime.
One third (30.2%, 180/597) of  K. pneumoniae  blood 
isolates were piperacillin-resistant and a quarter 
(25.5%, n = 152) were resistant to ampicillin-sulbactam. 
For the extended-spectrum cephalosporins, 27.0% 
(n = 161) isolates were resistant to cefotaxime, 20.8% 
(n = 124) to ceftazidime and 20.6% (n = 123) to 
cefepime. Carbapenem resistance was identified more 
frequently in  K. pneumoniae  blood isolates than in  E. 
coli (Figures 3 and 4). The resistance rate to ciprofloxa-
cin was 20.8% (n = 124), and those to amikacin and 
gentamicin were 3.4% (n = 20) and 13.6% (n = 81), 
respectively. Colistin resistance was identified in 0.8% 
(n = 5) isolates. K. pneumoniae urine isolates exhibited 
higher rates of resistance to the antimicrobials tested 
than the blood isolates. Carbapenem resistance rates 
in the 1,097 urine isolates were 1.0% (n = 11) to imipe-
nem, 1.0% (n = 11) to meropenem, and 1.3% (n = 14) 
to ertapenem. Colistin resistance was detected in 
1.0% (n = 11) isolates. The proportion of antimicrobial 
resistance in  K. pneumoniae  of HO was higher than 
in those of CO and the difference between them was 
larger in blood isolates (ca. three times higher) than in 
urine isolates (ca. 1.5 times higher). Most of the 604 
Cefotaxime-non-susceptible isolates were MDR (77.6%, 
n = 469) or XDR (20.9%, n = 126).
Among 44  Salmonella  blood isolates, one isolate was 
resistant to cefotaxime and intermediate to ceftazi-
dime. All the isolates remained susceptible to imipe-
nem. None was resistant to ciprofloxacin, however, 10 
were intermediate to the drug, and colistin resistance 
was observed in four. Five of the 77  Salmonella  stool 
isolates were cefotaxime-resistant, and four of those 
five were also resistant to ceftazidime. Similar to the 
blood isolates, all stool isolates were also susceptible 
to imipenem and 12 isolates were intermediate to cip-
rofloxacin. Three isolates were resistant to colistin.
Glucose non-fermenting Gram-negative bacilli
Non-susceptibility to piperacillin in P. aeruginosa blood 
isolates was observed in 21 of 127 (16.5%) isolates, 
and supplementing tazobactam had no effect on the 
susceptibility proportion (82.7%, n = 105) (Figures 
3  and  4). The proportion of resistance to ceftazidime 
and cefepime was 11.8% (n = 15) and 12.6% (n = 16), 
respectively. Rates of carbapenem resistance were 
18.1% (n = 23) for imipenem and 15.7% (n = 20) for 
meropenem. In addition, 6.3% (n = 8) of isolates were 
resistant to amikacin, 9.4% (n = 12) to gentamicin, 
8.7% (n = 11) to tobramycin and 15.0% (n = 19) to cipro-
floxacin. All isolates remained susceptible to colistin. 
Twice as many HO than CO isolates were non-suscep-
tible to the drug. The amikacin-non-susceptible  P. 
aeruginosa  blood isolates were mostly XDR (8/9) with 
the exception of one MDR isolate. In contrast, 14 of 30 
among the imipenem-non-susceptible isolates were 
XDR, four were MDR and 12 were DR.
The proportion of AMR in the 188 A. baumannii blood 
isolates was higher than 70% for all tested drugs 
(Figures 3  and  4) and the AMR proportion in HO iso-
lates was ca. twice that of CO isolates. Minocycline, 
tigecycline and colistin were still active in 93.1% 
(n = 175), 85.6% (n = 161) and 99.5% (n = 187) of iso-
lates, respectively. Among the A. baumanniiblood iso-
lates, 76.1% (n = 143) and 13.8% (n = 26) were XDR and 
MDR, respectively, and all but two MDR isolates were 
imipenem-non-susceptible. NBA blood isolates had a 
markedly lower proportion of AMR than A. baumannii.
The estimated prevalence of major AMR 
pathogens
In general, the AMR proportion of major pathogens for 
ICU patients was higher than for GW and OPD patients 
(Supplement: supplementary figure 3). BSI occurrence 
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by major AMR pathogen in inpatients per 10TPD (Figure 
5) had the highest mean value of 2.1 for cefotaxime-
resistant E. coli  (CXREC), followed by 1.6 for MRSA, 1.1 
for imipenem-resistant  A. baumannii, 0.8 for cefotax-
ime-resistant  K. pneumoniae  (CXRKP), 0.4 for VREFM, 
0.2 for penicillin-resistant  Ent. faecalis  (PREFA) and 
0.2 for imipenem-resistant  P. aeruginosa. As shown 
in  Figure 5, the ratio of BSI occurrence of the major 
AMR pathogens was much higher in ICU than on GW. 
Mean UTI occurrence in inpatients per 10TPD was 
higher for CXREC at 7.7 than for CXRKP at 2.1. The ratio 
of UTI occurrence in ICU vs GW was higher for CXRKP at 
2.4 than for CXREC at 1.5. 
Discussion
De Kraker et al. [9] described an increasing trend in 
the overall incidence of bacteremia caused by the 
top five pathogens (E. coli,  Sta. aureus,  Str. pneumo-
niae, Ent. faecalis and Ent. faecium) between 2002 and 
2008, based on the European Antimicrobial Resistance 
Surveillance Network (EARS-Net;  https://ecdc.
europa.eu/en/about-us/networks/disease-networks-
and-laboratory-networks/ears-net-about) database. 
Predominance of E. coli among pathogens causing BSIs 
is a common phenomenon worldwide. We assessed the 
relative incidence of BSIs caused by  E. coli  compared 
with other species: The relative ratio of  E. coli  to  Sta. 
aureus  in Kor-GLASS was moderate at 2.6, which was 
lower than the 3.2 observed in Norway [10], similar to 
the ratios of 2.4 in Taiwan [11] and 2.2 in Netherlands 
[12], and higher than the ratios of 1.2 in Japan [13], 1.2 
in Vietnam [14], 1.0 in Greece [15] and 1.1 in Malawi [16]. 
The relative ratio of  E. coli  to  K. pneumoniae  in South 
Korea was also moderate at 2.6, lower than in Northern 
European countries (5.4 in the Netherlands and 5.0 
in Norway), similar to 2.5 in Japan and 3.0 in Taiwan, 
and higher than 1.0 in Vietnam.  Str. pneumoniae  was 
frequently isolated from blood in European countries 
(relative ratio of  E. coli  to  Str. pneumoniae: 3.2 in the 
Netherlands, 3.1 in Norway and 4.1 in Spain), but rarely 
identified in South Korea (ratio: 54.9) which was simi-
lar to Asian countries (ratio: 18.3 in Vietnam and 31.8 in 
Taiwan). The Salmonella spp. is still a major pathogen 
causing BSI in developing countries such as Vietnam 
(relative ratio of  E. coli  to  Salmonella  spp.: 1.4) and 
Malawi (ratio: 0.2), however, this species was seldom 
identified in South Korea (ratio: 34.9), similar to the 
ratios 28.1 in Spain and 14.3 in Taiwan.
Sta. aureus  was the second most common pathogen 
causing BSI following  E. coli. BSI caused by  Sta. 
aureus  occurred in 2.8 inpatients per 10TPD in our 
study, which is 1.8-fold more than the 1.6 inpatients 
per 10TPD measured in 2011 in a previous prospective 
multi-center study in South Korea [17]. Since the sur-
veillance system of that study is not compatible to 
Kor-GLASS, the potential increase in  Sta. aureus-BSI 
needs to be further followed up. Similarly, we observed 
an increased incidence of MRSA-BSI at 1.6 inpatients 
per 10TPD compared with 1.2 inpatients per 10TPD in 
2011. This incidence was 2.5 times higher than the 0.62 
inpatients per 10TBD reported in a Canadian surveil-
lance study in 2014 [18]. The high prevalence of MRSA 
in blood isolates in South Korea has decreased from 
72% in 2013 to 66% in 2015 as measured by KARMS [4] 
and further to 54.3% in 2016 according to Kor-GLASS 
data. EARS-Net reported similarly that the percentage 
of MRSA has decreased from 18.1% in 2013 to 13.7% in 
2016 [9]. In addition, MRSA occurred more frequently 
in ICU patients than in GW patients (5.8 vs 1.1), indicat-
ing that MRSA is a problem in ICUs.
Enterococci have become a major cause of BSIs glob-
ally, owing to their intrinsic resistance to various anti-
biotics and their enormous ability to acquire resistance 
to antimicrobials.  Ent. faecium  and  Ent. faecalis  were 
the fourth and sixth most common pathogens causing 
BSI in inpatients in our study, with 1.2 and 0.8 BSI 
occurrences per 10TPD, respectively, and they caused 
over four times more BSI in ICUs than on GWs.  Ent. 
faecium  exhibited remarkably higher resistance 
rates than  Ent. faecalis  to ampicillin (90.3% vs 0.6%) 
and vancomycin (29.1% vs 0.6%), resulting in the 
identification of 1.3-fold more  Ent. faecium  than  Ent. 
faecalis, similar to the 1.8-fold difference found in Spain 
[19]. A reversed ratio was observed in the Netherlands 
(0.8:1) [14], and Japan (0.7:1) [12], countries that have 
low rates of AMR to these drugs. The vancomycin 
resistance rate (29.1%) in Ent. faecium was higher than 
that of teicoplanin (18.4%) in South Korea, although 
all isolates were  vanA-positive. This might be caused 
by the dissemination of clones with a vanA genotype–
VanA phenotype along with a  vanA  genotype–VanD 
phenotype following inactivation of  vanYand  vanZ  in 
the  vanA  operon by rearrangement of Tn1546  [20]. 
PREFA was also a common BSI-causative AMR patho-
gen, especially in ICUs. Clinical impacts of the penicil-
lin resistance need to be further investigated.
Both  E. coli  and  K. pneumoniae  exhibited higher 
resistance rates to cefotaxime than to ceftazidime owing 
to the dissemination of CTX-M-type extended-spectrum 
β-lactamases (ESBLs). The difference in the resistance 
rates to these drugs was greater in  E. coli  than in  K. 
pneumoniae,  which could have two possible causes: 
higher prevalence  K. pneumoniae  compared with  E. 
coli (i) of CTX-M group 1 ESBLs, which have an expanded 
hydrolytic activity to ceftazidime, and (ii) of SHV-type 
ESBLs, which hydrolyse both cefotaxime and ceftazi-
dime [21,22]. Identification of carbapenemase-produc-
ing Enterobacteriaceae (CPEs) in our surveillance study 
seemed the tip of an iceberg of the notorious AMR 
pathogen disseminated in clinical settings. All CPEs 
we identified were  K. pneumoniae  carbapenemase 
(KPC) producers. Continuous monitoring and action 
plans for CPEs are required because various types of 
carbapenemases, including KPC, New Delhi metallo-
β-lactamase and OXA-48-likes, have been introduced 
to South Korea during the last decade [23-25]. Colistin 
resistance in Enterobacteriaceae was rare in our study 
and none contained the mobile colistin resistance 
(mcr) genes  mcr-1  to  mcr-5  [26-28], although clinical 
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Enterobactericeae isolates carrying the  mcr-1  gene 
have already been reported in South Korea [29].
Amikacin non-susceptibility was a better indicator for 
XDR  P. aeruginosa  than imipenem-non-susceptibility. 
The carbapenemase-producing  P. aeruginosa  strains 
in South Korea harboured a class 1 integron carrying 
several resistance gene cassettes coding not only for 
a carbapenemase, but also for aminoglycoside-mod-
ifying enzymes [30]. Thus, most of the amikacin-non-
susceptible isolates were XDR. However, carbapenem 
resistance in  P. aeruginosastrains was conferred not 
only through acquisition of a gene for carbapenemase, 
but also through loss or alteration of the intrinsic OprD 
porin or overproduction of the efflux pumps [31], which 
rarely confer resistance to amikacin to the bacterial 
hosts.
BSIs caused by A. baumannii strains mostly occurred in 
ICUs rather than on GWs [32]. The likely reason is that 
the  A. baumannii  BSIs originated predominantly from 
pulmonary infections associated with ventilators. The 
rate of carbapenem resistance in A. baumannii strains 
was markedly high at 89.9% and most of these strains 
were XDR. This result is in line with previous reports 
from South Korea, and the resistance was mostly 
associated with OXA-23 carbapenemase production 
[33].
Conclusion
The Kor-GLASS, which performs strain collection and 
centralised analysis, was launched and operated. It 
provided well-curated surveillance data devoid of col-
lection bias or isolate duplication, including patient 
data associated with the bacterial cultures. In addition, 
frequency of infection occurrence by patient-days was 
estimated for comparison with foreign countries. The 
results of this surveillance helped plan national action 
in response to the high rate of drug resistance. A bacte-
rial bank and a database for the collections are under 
development.
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